Chicago Partners Investment Group 13F: Adds $6.1M to BSX Stake
Key Points
- Chicago Partners Investment Group boosted its stake in Boston Scientific by 134,169 shares, increasing its total holdings to 179,962 shares.
- As of October 27, 2026, Boston Scientific shares traded at $45.06, which is about equal to its recent price of $45.08.
- The fund's total reported value of its Boston Scientific position is approximately $8.2 million, representing a 0.54% share of its portfolio.
Get Boston Scientific text alerts
We text you when insiders, Congress, analysts or big funds move on $BSX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
On October 27, 2026, Chicago Partners Investment Group increased its position in Boston Scientific Corporation (BSX) by 134,169 shares, raising its total to 179,962 shares valued at approximately $8.2 million. This information comes from the fund's latest Form 13F filing with the SEC.
BSX
Boston Scientific Corporation
Chicago Partners Investment Group vs. the S&P 500
Hypothetical returns from Chicago Partners Investment Group's disclosed trades, not real profit or advice. How we model this.
What Changed in Chicago Partners Investment Group's Boston Scientific Position
Chicago Partners Investment Group added 134,169 shares, a 293% increase from the previous total of 45,793 shares. The total reported value of this position is about $8.2 million within a fund that has a total reported value of approximately $1.51 billion.
Where Boston Scientific Fits in Chicago Partners Investment Group's Portfolio
Boston Scientific now represents 0.54% of Chicago Partners Investment Group's portfolio, ranking 28th among its 1,660 positions.
Boston Scientific Corporation Stock Down 1.3%
As of October 27, 2026, Boston Scientific shares closed at $45.06, which is about equal to its recent price of $45.08. The stock is trading significantly below its 52-week high of $105.65, down about 57.3%. It is also trading below its 200-day moving average by about 21.7%.
Recent Earnings
Boston Scientific reported trailing twelve-month revenue of approximately $20.99 billion, with an earnings per share (EPS) of $2.47. The company has a net margin of 17.5% and a return on equity (ROE) of 15.3%. The next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Several insiders have made purchases recently. CEO Michael F. Mahoney bought 186,240 shares at an average price of $48.33 on August 3, 2026, totaling about $9 million. Additionally, Director David C. Habiger purchased 3,282 shares across two transactions on August 4 and August 5, totaling approximately $159,000. Director Susan E. Morano also bought 2,040 shares on August 25 for about $100,408.
Analysts Set New Price Targets
On October 26, 2026, Stifel maintained a "Buy" rating with a target of $55.0. Truist Securities also maintained a "Buy" rating but reduced its target to $51.0 on October 14, 2026. Overall, the consensus among analysts is a "Buy" rating with a mean price target of $57.82 based on 28 opinions.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for various medical specialties worldwide, operating mainly in the MedSurg and Cardiovascular segments. The company is based in Marlborough, Massachusetts, and employs around 59,000 people.
Bottom Line
Watch for Boston Scientific's next earnings report on October 28, 2026, as the company continues to navigate a challenging market environment. Chicago Partners Investment Group's recent boost in its stake illustrates its confidence in the company despite current trading levels.
Related Filing Alerts
Source: Chicago Partners Investment Group's 13F filing on $BSX (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts